Status and phase
Conditions
Treatments
About
The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
762 participants in 3 patient groups
Loading...
Central trial contact
Weixia Li, Master; Quanren Wang, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal